Calliditas Therapeutics Investor Relations Material
Latest events
Q2 2024
Calliditas Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Calliditas Therapeutics
Access all reports
Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Its lead product candidate is Nefecon that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden.
Key slides for Calliditas Therapeutics
Q2 2024
Calliditas Therapeutics
Q2 2024
Calliditas Therapeutics
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
CALTX
Country
🇸🇪 Sweden